Natural Course of Initially Metabolic Healthy Obese Individuals (Healthy Obesity)?
The main goal of this study is to gain a thorough understanding, which specific factors drive the unhealthy sequelae of obesity. Therefore, the investigators want to understand:
- What distinguishes obese persons without metabolic diseases from those with medical diseases in a cross-sectional comparison?
- Which factors drive the conversions from metabolically healthy obesity into a metabolically unhealthy obesity in a longitudinal approach?
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jörg Goldhahn, Prof.
- Phone Number: 044 633 70 54
- Email: jgoldhahn@ethz.ch
Study Contact Backup
- Name: Susanne Müller, MSc
- Phone Number: 044 633 70 54
- Email: susanne.mueller@dtip.ethz.ch
Study Locations
-
-
-
Baden, Switzerland, 5404
- Recruiting
- dTIP / ETH Zürich
-
Contact:
- Susanne Müller
- Email: susanne.mueller@dtip.ethz.ch
-
Contact:
- Sonia Strangio
- Email: sonia.strangio@dtip.ethz.ch
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed Informed Consent Form
- Age between 18 and 60 years
- BMI 30-50 kg/m2
- Knowledge of German, which requires sufficient written and allow oral patient education
Inclusion criteria for initially healthy group
- Blood pressure < 140/90 mmHg
Normal glucose metabolism
- HbA1c < 6.5 %
- Fasting Glucose < 7.0 mmol/l
Normal lipid metabolism
o LDL-cholesterol < 5.0 mmol/l
- ≤ 2 of the following metabolic syndrome criteria combined (excluding waist circumference)
- TG > 1.7 mmol/l
- HDL-cholesterol > 1.0 mmol/l (male) / > 1.3 mmol/l (female)
- Fasting glucose ≥ 5.6 mmol/l
- BP ≥ 130/85 mmHg
Exclusion Criteria:
- Pregnancy
- Medication and / or pathologies that prevent a safe execution of the fat tissue biopsies
- History of or planned bariatric operation
- Medical conditions that prevent examinations and testing (e.g. symptomatic cardiovascular diseases)
- Active Malignant tumor (<2a remission)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of conversion
Time Frame: Conversion will be driven by the occurrence of pathological findings caused by obesity (metabolic or cardiovascular pathologies). Through study completion, an average of 1 year.
|
The primary endpoint is the conversion (through study completions, 10 years) from obese but metabolically healthy subjects into obese patients in a pathological metabolic state, through study completion an average of 1 year.
|
Conversion will be driven by the occurrence of pathological findings caused by obesity (metabolic or cardiovascular pathologies). Through study completion, an average of 1 year.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of identification of factors
Time Frame: Conversion will be driven by the occurrence of pathological findings caused by obesity (metabolic or cardiovascular pathologies), through study completion, an average of 1 year.
|
The secondary endpoint is the identification of factors alone or in combination (through study completions, 10 years), that related to this conversion from healthy into pathological obesity.
This includes factors like: DEXA scans, White Adipose Tissue, lipid and glucose metabolism, vital signs, physical activity, general health and quality of life status...
|
Conversion will be driven by the occurrence of pathological findings caused by obesity (metabolic or cardiovascular pathologies), through study completion, an average of 1 year.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Jörg Goldhahn, Prof., dTIP / ETH Zürich
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2020-03031
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.